Results 131 to 140 of about 25,067 (205)

<i>LincRNA-BC7</i> as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer. [PDF]

Epigenomes
Fadebi OO, Alabi BA, Khanyile R, Dlamini Z, Marima R.   +4 more
europepmc   +1 more source

Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2. [PDF]

ESMO Open
Joris S, Denys H, Collignon J, Rasschaert M, de Roodenbeke DT, Duhoux FP, Canon JL, Tejpar S, Mebis J, Decoster L, Aftimos P, De Grève J.   +11 more
europepmc   +1 more source

PPAR-γ agonist Inactivate Cellular Senescence by Inhibiting SIRT1 Signaling to Confer Increased Sensitivity to Olaparib in Ovarian Cancer Cells. [PDF]

Saudi J Med Med Sci
Wang Z, Miao W, Gao J, Zhang X.
europepmc   +1 more source

Triple M Syndrome Associated With Concurrent Durvalumab and Olaparib Therapy in Metastatic Cholangiocarcinoma: A Case Report. [PDF]

Case Rep Oncol Med
Nilsen O, Senko C, Collins A, Tomkins N, Buckley D, Weickhardt A, Tebbutt N.   +6 more
europepmc   +1 more source

PARP Inhibitors as Radiosensitizers: Current Evidence and Future Directions. [PDF]

Curr Oncol Rep
Pereira E, Pereira F, Campos G, Abrantes AM, Botelho MF, Silva-Vaz P, Pires AS.   +6 more
europepmc   +1 more source

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [PDF]

RSC Adv
Rani D, Plebanski M, Chatterjee T.
europepmc   +1 more source

Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors. [PDF]

NAR Cancer
Buckley-Benbow L, Ozgencil M, Tardocchi A, Agnarelli A, Bellelli R.   +4 more
europepmc   +1 more source

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. [PDF]

EClinicalMedicine
Morgan RD, Porter C, Zhou C, Kristeleit R, Desai S, Vazquez I, George A, Eminowicz G, Walther A, Franklin A, Sadozye AH, Hughes A, Hanna L, Roux R, Lord R, Bowen R, Wood J, Sentamans C, White A, Casbard AC, Humphrys A, Swettenham JB, Nixon LS, Adams R, Ray R, Brogden E, Powell WE, Canham J, Cox TM, Narasimham M, Lowe H, Ensell L, Zubair M, Morris K, Glenister-Doyle M, Gassio AF, Morgan D, Broughton D, Carucci M, Monaghan PJ, Tugwood J, Edmondson RJ, Dive C, Jayson GC, Clamp AR.   +44 more
europepmc   +1 more source

Poly(ADP-ribose) polymerase inhibitor maintenance therapy in ovarian cancer: a single-center retrospective study. [PDF]

Front Oncol
Pence S, Dyson K, Waters K, Elliott JO, Rath K, Pierce S, Harper A, Calo C, Clements AE.   +8 more
europepmc   +1 more source

Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review. [PDF]

Gynecol Oncol Rep
Arab W, Kassis NE, Khoury C, Mansour H, Chahine G, Atallah D.   +5 more
europepmc   +1 more source